Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer

• DOI: 10.21873/anticanres.13253
• Publication Date: 2019-03-06T21:19:13Z
• Authors: HIDEAKI MIYAKE; YUTO MATSUSHITA; HIROMITSU WATANABE; KEITA TAMURA; DAISUKE MOTOYAMA; TOSHIKI ITO; TAKAYUKI SUGIYAMA; ATSUSHI OTSUKA
• Keywords: Univariate analysis

Background/Aim: It is important to delay the emergence of castration-resistant phenotype improve prognosis in patients with metastatic castration-sensitive prostate cancer (mCSPC). The objective this study was investigate prognostic impact time castration resistance (TTCR) mCSPC patients. Patients and Methods: This included 437 consecutive whose primary androgen deprivation therapy judged have failed. Prognostic outcomes these were investigated by dividing them into following 4 groups 82, 104, 133 118 TTCR 0-6, 6.1-12, 12.1-18 ≥18.1 months, respectively. Results: mean value 18.7 months. Of several baseline parameters, significant differences among noted performance status, prostate-specific antigen (PSA) level, lactate dehydrogenase (LDH) alkaline phosphatase (ALP) level Gleason score, all which favored longer groups. Furthermore, despite lack a difference from development disease death groups, there overall survival (OS) diagnosis showing prolonged OS proportional TTCR. Univariate analysis identified age, PSA LDH ALP visceral metastasis as predictors OS, only shown be independently associated on multivariate analysis. Conclusion: are likely achieve more favorable OS.